The COVID-19 saliva-based screening market was valued at about US$ 1.7 billion in 2020, and, according to Persistence Market Research’s most recent industry analysis, it will decline at a CAGR of -3% from 2022 to 2031.
Currently, COVID-19 saliva-based screening is gaining popularity since it is patient-friendly, simple to use, and results are available more quickly. By screening asymptomatic individuals, COVID-19 saliva-based screening actively contributes to market growth. This is mostly because saliva-based tests have several benefits, the FDA is approving more products, and point-of-care testing is becoming more popular.
The COVID-19 epidemic has caused a number of major firms to enter the screening market. Marketing revenue is also greatly influenced by advertising and growth initiatives. Additionally, manufacturers are making significant investments in R&D projects to provide unique methodologies that enable quick testing and precise findings.
Visit https://www.persistencemarketresearch.com/samples/32712 to obtain a free sample copy of this report.
In this market segment, product launches, approvals, and acquisitions and mergers are commonplace:
• Abbott introduced ID NOW, a molecular POCT for identifying new coronaviruses (COVID-19), which was approved under an Emergency Use Authorization from the U.S. FDA (EUA). It is compact, lightweight (6.6 pounds), portable, and uses molecular technology to produce positive results in as little as five minutes and negative results in as little as thirteen minutes.
• In April 2021, Chembio Diagnostics, Inc. announced the availability of a quick POCT for COVID-19/Flu A&B test with an FDA emergency use authorisation that may be used in both decentralised and conventional testing environments.
• Mesa Biotech, a producer of portable test instruments for COVID-19 detection, was purchased by Thermo Fisher Scientific. Mesa earned about US$ 450 million in cash and qualified for an extra US$ 100 million upon reaching a number of previously stated milestones. Thermo Fisher Scientific was able to speed up the availability of trustworthy and precise advanced molecular diagnostics at POCT because to this acquisition.
Profiles of companies:
Thermo Fisher Scientific, Qiagen, All Pharma, Kolplast Group, Lucence Health Inc., Vitagene, Therma Bright Inc., ACON Laboratories, Inc., Hologic, Takara Bio Inc., Arcis Biotechnology Limited, GeneProof, Abacus ALS, Chai Inc., Norgen Biotek Corp., Assure Tech. (Hangzhou) Co., Ltd., Beijing Hotgen Biotech Co., Ltd., Diagnos Biotechnology Co., Ltd. in Nantong, Salimetrics, NEST Scientific USA, Miraclean Technology Co. Ltd, Mawi DNA Technologies, Cell Projects Ltd., NeuMoDx Molecular, Inc., KYODO INTERNATIONAL INC., Canvax, Zymo Research Corporation, etc.
Key Market Study Conclusions
Based on product, saliva-based detection kits command the market with a share of over 83%.
The global market value share of RT-qPCR technology, measured by technology, is approximately 49%. This is primarily because research activities and the emphasis on speedy testing are expanding.
By application, COVID-19 diagnostics is predicted to rule the market. This sector held a 63% market share, primarily as a result of the increased incidence of COVID-19 and the rising need for COVID-19 diagnostics.
With a market share of 27%, diagnostic laboratories lead the industry among end users.
With a value share of roughly 36% in the global market, Europe is predicted to lead all other regions.
Through 2031, North America is anticipated to hold the second-largest share of the leading market, with a value share of 34%.
According to a Persistence Market Research analyst, the growing use of COVID-19 saliva-based screening, an ageing population that is more susceptible to the virus, and ongoing government guidance to support the pandemic’s response effect will all contribute to market growth in the upcoming years.
Marketplace rivalry
Leading players’ key growth strategies now centre on new product approvals, launches, collaborations, agreements, and partnerships. A corporation can increase the range of its products by making acquisitions. The acquired company has established diagnostic products and solutions, which provide the acquirer with a reliable source of income. This allows the business to expand into both current markets and new, emerging ones.
Vatic Health received the CE mark in April 2021 for a saliva antigen test that serves as an immediate diagnostic tool for the SARS-CoV-2 virus. The test has also been registered with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).
